Purple Biotech Ltd.
PPBT Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$1.17
KIRA · Stoqly’s AI analyst, in plain words
- Purple Biotech Ltd. lost $26.4M in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew −38.4% a year.
- Free cash flow was −$5.7M in fiscal 2025. At that burn of $5.7M a year, its $8.7M of cash and short-term investments would last about 1.5 years.
Market cap
—
P/E
—
Revenue
—
Net income
−$26.4M
Free cash flow
−$5.7M
Operating margin
—
Purple Biotech Ltd. in 30 seconds · fiscal 2025
Does it make a profit?
−$26.4M
No. It lost money last year.
How long would its cash last?
1.5 yrs
For now. It burns $5.7M a year and holds $8.7M, about 1.5 years at that pace.
What Purple Biotech Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 19, 2026
- Legal name
- PURPLE BIOTECH LTD.
- CIK
- 0001614744
Purple Biotech Ltd. · PPBT · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | $18.4M | −$21.7M | −$19.9M | −$7.2M | −$26.4M |
| Diluted EPS | $17,568,036.00 | $23.97 | $17.96 | $4.99 | $0.03 |
| Cash | |||||
| Cash from operations | −$0.4M | −$16.7M | −$19.9M | −$14.4M | −$5.7M |
| Capital expenditure | $0.1M | $0.0M | $0.0M | — | $0.0M |
| Free cash flow | −$0.5M | −$16.8M | −$19.9M | — | −$5.7M |
| Share count change | 52.8% | −94.9% | 22.4% | 48.2% | −70.7% |
| Debt and strength | |||||
| Cash and short-term investments | $10.9M | $15.0M | $14.5M | $7.4M | $8.7M |
| Shareholders' equity | $64.8M | $46.9M | $34.2M | $32.9M | $9.7M |
| Current ratio | 11.4x | 4.7x | 1.6x | 2.2x | 1.3x |
| Interest coverage | — | −337.4x | −10.1x | — | — |
| Returns and quality | |||||
| Return on equity | 25.5% | −38.8% | −49.0% | −21.6% | −124.0% |
| Return on tangible equity | 41.5% | −82.6% | −322.6% | −144.3% | −1,120.9% |
| Altman Z'' | 10.6 | −0.3 | −9.0 | — | — |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Purple Biotech Ltd. · PPBT · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.17 a share, the company is worth —.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001614744). Latest version: stoqly.net/companies/ppbt. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.